07:00 , Mar 9, 2015 |  BioCentury  |  Finance

Column's creations

Including milestones, Bristol-Myers Squibb Co .'s takeout of Flexus Biosciences Inc. late last month is enough to return the capital of The Column Group's entire second fund. While it's the third quick exit for TCG,...
07:00 , Sep 4, 2006 |  BC Week In Review  |  Company News

Breakthrough Therapeutics, MolecularMD deal

Under a two-year deal, MolecularMD will monitor residual disease levels in patients in a Phase II trial of Breakthrough's Ablvax (VAX100) vaccine to treat Gleevec-resistant chronic myeloid leukemia (CML). MolecularMD will measure patients' Bcr-Abl transcript...
07:00 , Aug 28, 2006 |  BC Week In Review  |  Company News

Cellumen board of directors update

Cellumen Inc. , Pittsburgh, Penn.   Business: Proteomics   Appointed: Rosemary Mazanet, CEO of Breakthrough Therapeutics LLC and acting CEO of Access Pharmaceuticals Inc.  ...
07:00 , Jun 5, 2006 |  BioCentury  |  Product Development

ALL/CML pipeline

ALL/CML pipeline ALL/CML pipeline Selected therapeutics in clinical development for acute lymphoblastic leukemia (ALL) and/or chronic myelogenous leukemia (CML). (A) Already marketed for ALL patients who are hypersensitive to native L-asparaginase; (B) In-licensed exclusive worldwide...
08:00 , Jan 9, 2006 |  BC Week In Review  |  Clinical News

VAX100: Phase I/II data

Two-year follow-up data from an open-label, U.S. and Italian Phase I/II study in 18 evaluable patients, who had stable residual disease and showed no improvement for a minimum of 12 months after treatment with Gleevec...
08:00 , Jan 9, 2006 |  BC Week In Review  |  Clinical News

VAX100: Phase II started

Breakthrough began an open-label, U.S. Phase II trial in 40 to 80 patients treated with Gleevec . Novartis AG (NVS; SWX:NOVN) markets Gleevec imatinib. Breakthrough Therapeutics LLC , Greenwich, Conn.   Product: VAX100   Business:...
00:45 , May 12, 2005 |  BC Extra  |  Company News

Access CEO Gray resigns

AKC said Kerry Gray resigned as president, CEO and a director. Rosemary Mazanet, CEO of Breakthrough Therapeutics (Greenwich, Conn.) and a consultant, will serve as acting CEO while the company searches for a permanent replacement....
08:00 , Mar 7, 2005 |  BC Week In Review  |  Clinical News

VAX100 cancer data

Data from a trial in 16 patients showed that VAX100 vaccine reduced persistent disease in CML patients who have had stable disease with imatinib or interferon alpha therapy. Six vaccinations of VAX100 every other week...
07:00 , Oct 18, 2004 |  BioCentury  |  Regulation

Two mouths, if not one voice

Starting next year, companies filing an IND, NDA, BLA or MAA will be able to apply for parallel scientific advice from both FDA and EMEA as a result of the recently disclosed cooperation agreement between...